Status:

COMPLETED

Prospective Evaluation of Residual Bile Duct Stone by Peroral Cholangioscopy After Conventional ERCP

Lead Sponsor:

Northwell Health

Collaborating Sponsors:

Boston Scientific Corporation

Conditions:

Gall Stones

Eligibility:

All Genders

18+ years

Brief Summary

Gallstone disease affects over 20 million Americans. Among patients with gallbladder disease, the prevalence of choledocholithiasis (stones in the bile duct) is estimated to be 10-20%. Endoscopic retr...

Detailed Description

Peroral cholangioscopy (POC) provides direct visualization of the bile duct during ERCP and its benefits are well documented in numerous published studies. POC has been described for therapy of diffic...

Eligibility Criteria

Inclusion

  • Patient receiving ERCP as standard of care for suspected or documented choledocholithiasis as assessed by one or more of the following:
  • Abnormal imaging on ultrasound, endoscopic ultrasound (EUS), CT scan, or MRCP suggestive of choledocholithiasis
  • Clinical signs and symptoms suggestive of choledocholithiasis such as jaundice, abdominal pain, pruritis, pancreatitis, and/or cholangitis
  • Abnormal liver function tests suggestive of choledocholithiasis (eg: serum bilirubin \> 1.5 and/or elevated alkaline phosphatase levels)
  • In addition to one or more of the above inclusion criteria, patient must also satisfy one or more of the following:
  • Mechanical lithotripsy, electrohydraulic lithotripsy, or laser lithotripsy performed for therapy of bile duct stones.
  • Bile duct \> 12mm on prior tests (any portion of duct)
  • History of recurrent abnormal LFTs with negative cholangiogram.
  • Positive EUS or MRCP for biliary stones with a negative cholangiogram

Exclusion

  • Patients less than 18 years of age.
  • Patients not undergoing ERCP as their standard of care.
  • Patients who had the following surgeries - Billroth II surgery, Roux-en-Y Gastric bypass surgery, and Whipple's surgery.

Key Trial Info

Start Date :

December 17 2015

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 10 2019

Estimated Enrollment :

140 Patients enrolled

Trial Details

Trial ID

NCT03482375

Start Date

December 17 2015

End Date

February 10 2019

Last Update

February 19 2019

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

North Shore University Hospital

Manhasset, New York, United States, 11030

2

LIJ Medical Center- NSLIJ Health System

New Hyde Park, New York, United States, 11040